Also relating to PDGF-B/PDGFR-β signaling, Lebrin et al. (2010) showed that the drug thalidomide reduced bleeding in patients with hereditary hemorrhagic telangiectasia (HHT), a disease involving vascular malformations and bleeds in multiple organs. The gene discussed is PDGFRB; the disease is hereditary hemorrhagic telangiectasia.